SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as glucose lowering therapies, with additional benefits of weight loss and blood pressure reduction. Data from cardiovascular outcome trials have highlighted that these drugs confer protection against major cardio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2021-07, Vol.398 (10296), p.262-276
Hauptverfasser:	Brown, Emily, Heerspink, Hiddo J L, Cuthbertson, Daniel J, Wilding, John P H
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Amputation Arteriosclerosis Atherosclerosis Blood pressure Body weight Body weight loss Cardiac patients Cardiovascular agents Cardiovascular diseases Chronic kidney failure Clinical trials Congestive heart failure COVID-19 Dextrose Diabetes Diabetes mellitus (non-insulin dependent) Diabetic ketoacidosis Disease control Drugs Ejection fraction Glomerular filtration rate GLP-1 receptor agonists Glucose Heart failure Hospitals Inhibitors Ketoacidosis Kidney diseases Kidneys Mortality Overweight Pancreatitis Patients Polyuria Pressure reduction Receptors Risk Thyroid Thyroid cancer Type 2 diabetes United Kingdom Urinary tract diseases Urinary tract infections Urogenital system Weight loss
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!